While aspirin may offer protection, other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious cardiovascular side effects and complications. This has led to a general "black box" warning for cardiovascular adverse events for NSAIDs. This review explores the different mechanisms underlying the protective effects of aspirin, the NSAID associated renovascular effects causing hypertension, edema and heart failure, the cardiovascular effects causing myocardial infarction and stroke, and the possible deleterious interaction between NSAIDs and aspirin.
References
[1]
Von Euler, U.S. Uber Die Specifische Blutdrucksenkende Substanz Des Menschlichen Prostate- Und Samenblasensekrets. Klin. Wochenschr.？1935, 14, 1182–1183.
[2]
Goldblatt, M.W. Properties of Human Seminal Plasma. J. Physiol.？1935, 84, 208–218.
[3]
Van, D.O.R.P.; Beerthuis, R.K.; Nugteren, D.H.; Vonkeman, H. Enzymatic conversion of all-cis-polyunsaturated fatty acids into prostaglandins. Nature？1964, 203, 839–841.
[4]
Van, D.O.R.P.; Beerthuis, R.K.; Nugteren, D.H.; Vonkeman, H. The biosynthesis of prostaglandins. Biochim. Biophys. Acta？1964, 90, 204–207.
[5]
Fu, J.Y.; Masferrer, J.L.; Seibert, K.; Raz, A.; Needleman, P. The Induction and Suppression of Prostaglandin H2 Synthase (Cyclooxygenase) in Human Monocytes. J. Biol. Chem.？1990, 265, 16737–16740.
[6]
Picot, D.; Loll, P.J.; Garavito, R.M. The X-Ray Crystal Structure of the Membrane Protein Prostaglandin H2 Synthase-1. Nature？1994, 367, 243–249.
[7]
Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M.F. Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2. Nat. Struct. Biol.？1996, 3, 927–933.
[8]
Smith, J.B.; Willis, A.L. Aspirin Selectively Inhibits Prostaglandin Production in Human Platelets. Nat. New Biol.？1971, 231, 235–237.
[9]
Collier, J.G.; Flower, R.J. Effect of Aspirin on Human Seminal Prostaglandins. Lancet？1971, 2, 852–853.
[10]
Vonkeman, H.E.; van de Laar, M.A. Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Semin. Arthritis Rheum.？2010, 39, 294–312.
[11]
Catella-Lawson, F.; Crofford, L.J. Cyclooxygenase Inhibition and Thrombogenicity. Am. J. Med.？2001, 110 Suppl. 3A, 28–32. 11173047
[12]
Baigent, C.; Blackwell, L.; Collins, R.; Emberson, J.; Godwin, J.; Peto, R.; Buring, J.; Hennekens, C.; Kearney, P.; Meade, T.; Patrono, C.; Roncaglioni, M.C.; Zanchetti, A. Aspirin in the Primary and Secondary Prevention of Vascular Disease: Collaborative Meta-Analysis of Individual Participant Data From Randomised Trials. Lancet？2009, 373, 1849–1860.
[13]
McQuaid, K.R.; Laine, L. Systematic Review and Meta-Analysis of Adverse Events of Low-Dose Aspirin and Clopidogrel in Randomized Controlled Trials. Am. J. Med.？2006, 119, 624–638.
[14]
Lanza, F.L. A Guideline for the Treatment and Prevention of NSAID-Induced Ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol.？1998, 93, 2037–2046, doi:10.1111/j.1572-0241.1998.00588.x. 9820370
[15]
Singh, G.; Rosen, R.D. NSAID Induced Gastrointestinal Complications: the ARAMIS Perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. J. Rheumatol. Suppl？1998, 51, 8–16. 9596549
[16]
Silverstein, F.E.; Graham, D.Y.; Senior, J.R.; Davies, H.W.; Struthers, B.J.; Bittman, R.M.; Geis, G.S. Misoprostol Reduces Serious Gastrointestinal Complications in Patients With Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs. A Randomized, Double-Blind, Placebo-Controlled Trial. Ann. Intern. Med.？1995, 123, 241–249. 7611589
[17]
Lai, K.C.; Lam, S.K.; Chu, K.M.; Wong, B.C.; Hui, W.M.; Hu, W.H.; Lau, G.K.; Wong, W.M.; Yuen, M.F.; Chan, A.O.; Lai, C.L.; Wong, J. Lansoprazole for the Prevention of Recurrences of Ulcer Complications From Long-Term Low-Dose Aspirin Use. N. Engl. J. Med.？2002, 346, 2033–2038.
[18]
Chan, F.K.; Chung, S.C.; Suen, B.Y.; Lee, Y.T.; Leung, W.K.; Leung, V.K.; Wu, J.C.; Lau, J.Y.; Hui, Y.; Lai, M.S.; Chan, H.L.; Sung, J.J. Preventing Recurrent Upper Gastrointestinal Bleeding in Patients With Helicobacter Pylori Infection Who Are Taking Low-Dose Aspirin or Naproxen. N. Engl. J. Med.？2001, 344, 967–973.
[19]
Adams, S.S. The Discovery of Brufen. Chem. Br.？1987, 23, 1193–1195.
[20]
Jasani, M.K.; Downie, W.W.; Samuels, B.M.; Buchanan, W.W. Ibuprofen in Rheumatoid Arthritis. Clinical Study of Analgesic and Anti-Inflammatory Activity. Ann. Rheum. Dis.？1968, 27, 457–462. 4283768
[21]
Flower, R.; Gryglewski, R.; Herbaczynska-Cedro, K.; Vane, J.R. Effects of Anti-Inflammatory Drugs on Prostaglandin Biosynthesis. Nat. New Biol.？1972, 238, 104–106.
[22]
Van, H.A.; Schwartz, J.I.; Depre, M.; De, L., I.; Dallob, A.; Tanaka, W.; Wynants, K.; Buntinx, A.; Arnout, J.; Wong, P.H.; Ebel, D.L.; Gertz, B.J.; De Schepper, P.J. Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 Versus COX-1 in Healthy Volunteers. J. Clin. Pharmacol.？2000, 40, 1109–1120. 11028250
Lanzo, C.A.; Beechem, J.M.; Talley, J.; Marnett, L.J. Investigation of the Binding of Isoform-Selective Inhibitors to Prostaglandin Endoperoxide Synthases Using Fluorescence Spectroscopy. Biochemistry？1998, 37, 217–226.
[25]
Brun, J.; Jones, R. Nonsteroidal Anti-Inflammatory Drug-Associated Dyspepsia: the Scale of the Problem. Am. J. Med.？2001, 110, 12S–13S.
Vonkeman, H.E.; Fernandes, R.W.; van de Laar, M.A. Under-Utilization of Gastroprotective Drugs in Patients With NSAID-Related Ulcers. Int. J. Clin. Pharmacol. Ther.？2007, 45, 281–288.
[28]
Armstrong, C.P.; Blower, A.L. Non-Steroidal Anti-Inflammatory Drugs and Life Threatening Complications of Peptic Ulceration. Gut？1987, 28, 527–532.
Graham, D.Y.; Agrawal, N.M.; Campbell, D.R.; Haber, M.M.; Collis, C.; Lukasik, N.L.; Huang, B. Ulcer Prevention in Long-Term Users of Nonsteroidal Anti-Inflammatory Drugs: Results of a Double-Blind, Randomized, Multicenter, Active- and Placebo-Controlled Study of Misoprostol Vs Lansoprazole. Arch. Intern. Med.？2002, 162, 169–175, doi:10.1001/archinte.162.2.169. 11802750
[31]
Bianchi, P.G.; Lazzaroni, M.; Imbesi, V.; Montrone, F.; Santagada, T. Efficacy of Pantoprazole in the Prevention of Peptic Ulcers, Induced by Non-Steroidal Anti-Inflammatory Drugs: a Prospective, Placebo-Controlled, Double-Blind, Parallel-Group Study. Dig. Liver Dis.？2000, 32, 201–208, doi:10.1016/S1590-8658(00)80821-X. 10975769
[32]
Koch, M.; Dezi, A.; Ferrario, F.; Capurso, I. Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Mucosal Injury. A Meta-Analysis of Randomized Controlled Clinical Trials. Arch. Intern. Med.？1996, 156, 2321–2332, doi:10.1001/archinte.1996.00440190069008. 8911239
[33]
Taha, A.S.; Hudson, N.; Hawkey, C.J.; Swannell, A.J.; Trye, P.N.; Cottrell, J.; Mann, S.G.; Simon, T.J.; Sturrock, R.D.; Russell, R.I. Famotidine for the Prevention of Gastric and Duodenal Ulcers Caused by Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med.？1996, 334, 1435–1439.
[34]
Chan, F.K.; To, K.F.; Wu, J.C.; Yung, M.Y.; Leung, W.K.; Kwok, T.; Hui, Y.; Chan, H.L.; Chan, C.S.; Hui, E.; Woo, J.; Sung, J.J. Eradication of Helicobacter Pylori and Risk of Peptic Ulcers in Patients Starting Long-Term Treatment With Non-Steroidal Anti-Inflammatory Drugs: a Randomised Trial. Lancet？2002, 359, 9–13.
[35]
Chan, F.K.; Sung, J.J.; Chung, S.C.; To, K.F.; Yung, M.Y.; Leung, V.K.; Lee, Y.T.; Chan, C.S.; Li, E.K.; Woo, J. Randomised Trial of Eradication of Helicobacter Pylori Before Non-Steroidal Anti-Inflammatory Drug Therapy to Prevent Peptic Ulcers. Lancet？1997, 350, 975–979.
[36]
Fitzgerald, G.A. Cardiovascular Pharmacology of Nonselective Nonsteroidal Anti-Inflammatory Drugs and Coxibs: Clinical Considerations. Am. J. Cardiol.？2002, 89, 26D–32D.
[37]
Vonkeman, H.E.; Brouwers, J.R.; van de Laar, M.A. Understanding the NSAID Related Risk of Vascular Events. BMJ？2006, 332, 895–898.
[38]
Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A. Cardiovascular Events Associated With Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N. Engl. J. Med.？2005, 352, 1092–1102.
[39]
Kearney, P.M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J.R.; Patrono, C. Do Selective Cyclo-Oxygenase-2 Inhibitors and Traditional Non-Steroidal Anti-Inflammatory Drugs Increase the Risk of Atherothrombosis? Meta-Analysis of Randomised Trials. BMJ？2006, 332, 1302–1308.
[40]
McGettigan, P.; Henry, D. Cardiovascular Risk and Inhibition of Cyclooxygenase: a Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA？2006, 296, 1633–1644.
[41]
Scott, P.A.; Kingsley, G.H.; Smith, C.M.; Choy, E.H.; Scott, D.L. Non-Steroidal Anti-Inflammatory Drugs and Myocardial Infarctions: Comparative Systematic Review of Evidence From Observational Studies and Randomised Controlled Trials. Ann. Rheum. Dis.？2007, 66, 1296–1304.
Garcia Rodriguez, L.A.; Tacconelli, S.; Patrignani, P. Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. J. Am. Coll. Cardiol.？2008, 52, 1628–1636.
[44]
Gislason, G.H.; Jacobsen, S.; Rasmussen, J.N.; Rasmussen, S.; Buch, P.; Friberg, J.; Schramm, T.K.; Abildstrom, S.Z.; Kober, L.; Madsen, M.; Torp-Pedersen, C. Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation？2006, 113, 2906–2913.
[45]
Fosbol, E.L.; Gislason, G.H.; Jacobsen, S.; Folke, F.; Hansen, M.L.; Schramm, T.K.; Sorensen, R.; Rasmussen, J.N.; Andersen, S.S.; Abildstrom, S.Z.; Traerup, J.; Poulsen, H.E.; Rasmussen, S.; Kober, L.; Torp-Pedersen, C. Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: a Nationwide Cohort Study. Clin. Pharmacol. Ther.？2009, 85, 190–197.
[46]
FDA Public Health Advisory: Alert for Healthcare Professionals Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available online: http://www.fda.gov/Drugs/DrugSafety/ (accessed on 7 July 2010).
[47]
European Medicines Agency update on review of non-selective NSAIDs. Available online: http://www.ema.europa.eu/htms/human/drugalert/drugalert.htm (accessed on 7 July 2010).
Bhatt, D.L.; Scheiman, J.; Abraham, N.S.; Antman, E.M.; Chan, F.K.; Furberg, C.D.; Johnson, D.A.; Mahaffey, K.W.; Quigley, E.M. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: a Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation？2008, 118, 1894–1909.
[50]
Antman, E.M.; Bennett, J.S.; Daugherty, A.; Furberg, C.; Roberts, H.; Taubert, K.A. Use of Nonsteroidal Antiinflammatory Drugs: an Update for Clinicians: a Scientific Statement From the American Heart Association. Circulation？2007, 115, 1634–1642.
[51]
Solomon, D. Nonselective NSAIDs: cardiovascular effects. UpToDate, Available online: http://www.uptodate.com/ (accessed on 30 June 2010).
[52]
Aw, T.J.; Haas, S.J.; Liew, D.; Krum, H. Meta-Analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure. Arch. Intern. Med.？2005, 165, 490–496.
[53]
Rose, B.D.; Post, T.W. NSAIDs: Acute renal failure and nephrotic syndrome. UpToDate, Available online: http://www.uptodate.com/ (accessed on 30 June 2010).
[54]
Feenstra, J.; Heerdink, E.R.; Grobbee, D.E.; Stricker, B.H. Association of Nonsteroidal Anti-Inflammatory Drugs With First Occurrence of Heart Failure and With Relapsing Heart Failure: the Rotterdam Study. Arch. Intern. Med.？2002, 162, 265–270.
[55]
Page, J.; Henry, D. Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: an Underrecognized Public Health Problem. Arch. Intern. Med.？2000, 160, 777–784.
[56]
Gislason, G.H.; Rasmussen, J.N.; Abildstrom, S.Z.; Schramm, T.K.; Hansen, M.L.; Fosbol, E.L.; Sorensen, R.; Folke, F.; Buch, P.; Gadsboll, N.; Rasmussen, S.; Poulsen, H.E.; Kober, L.; Madsen, M.; Torp-Pedersen, C. Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Chronic Heart Failure. Arch. Intern. Med.？2009, 169, 141–149.
[57]
Chan, C.C.; Reid, C.M.; Aw, T.J.; Liew, D.; Haas, S.J.; Krum, H. Do COX-2 Inhibitors Raise Blood Pressure More Than Nonselective NSAIDs and Placebo? An Updated Meta-Analysis. J. Hypertens.？2009, 27, 2332–2341.
[58]
Swan, S.K.; Rudy, D.W.; Lasseter, K.C.; Ryan, C.F.; Buechel, K.L.; Lambrecht, L.J.; Pinto, M.B.; Dilzer, S.C.; Obrda, O.; Sundblad, K.J.; Gumbs, C.P.; Ebel, D.L.; Quan, H.; Larson, P.J.; Schwartz, J.I.; Musliner, T.A.; Gertz, B.J.; Brater, D.C.; Yao, S.L. Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet. A Randomized, Controlled Trial. Ann. Intern. Med.？2000, 133, 1–9. 10877734
[59]
Schneider, V.; Levesque, L.E.; Zhang, B.; Hutchinson, T.; Brophy, J.M. Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-Based, Nested Case-Control Analysis. Am. J. Epidemiol.？2006, 164, 881–889.
[60]
Clive, D.M.; Stoff, J.S. Renal Syndromes Associated With Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med.？1984, 310, 563–572.
[61]
Wallace, J.L.; Viappiani, S.; Bolla, M. Cyclooxygenase-Inhibiting Nitric Oxide Donators for Osteoarthritis. Trends Pharmacol. Sci.？2009, 30, 112–117.
[62]
White, W.B.; Schnitzer, T.J.; Fleming, R.; Duquesroix, B.; Beekman, M. Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis. Am. J. Cardiol.？2009, 104, 840–845. 19733721
[63]
Catella-Lawson, F.; Reilly, M.P.; Kapoor, S.C.; Cucchiara, A.J.; DeMarco, S.; Tournier, B.; Vyas, S.N.; Fitzgerald, G.A. Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. N. Engl. J. Med.？2001, 345, 1809–1817.
[64]
Capone, M.L.; Sciulli, M.G.; Tacconelli, S.; Grana, M.; Ricciotti, E.; Renda, G.; Di, G.P.; Merciaro, G.; Patrignani, P. Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects. J. Am.. Coll. Cardiol.？2005, 45, 1295–1301.
[65]
Patrono, C.; Garcia Rodriguez, L.A.; Landolfi, R.; Baigent, C. Low-Dose Aspirin for the Prevention of Atherothrombosis. N. Engl. J. Med.？2005, 353, 2373–2383.
[66]
Fitzgerald, G.A. Parsing an Enigma: the Pharmacodynamics of Aspirin Resistance. Lancet？2003, 361, 542–544.
[67]
Richardson, C.G.; Chalmers, A.; Llewellyn-Thomas, H.A.; Klinkhoff, A.; Carswell, A.; Kopec, J.A. Pain Relief in Osteoarthritis: Patients' Willingness to Risk Medication-Induced Gastrointestinal, Cardiovascular, and Cerebrovascular Complications. J. Rheumatol.？2007, 34, 1569–1575. 17552039
